Director Raquel C. Bono filed a Form 4 with the SEC on October 20, 2026, disclosing the acquisition of 78,800 shares of common stock and a stock option covering 157,400 shares of Vaxart, Inc. (NASDAQ:VXRT), both granted on October 16, 2026.

Key Highlights

  • RSU grant: Raquel C. Bono acquired 78,800 shares of common stock at $0 per share on October 16, 2026, upon vesting of restricted stock units.
  • Stock option grant: Bono also received a stock option to purchase 157,400 shares of common stock, with an exercise price of $0.4527, expiring October 16, 2036.
  • Vesting schedule: Both the RSU award and the stock option vest in equal installments on each of the first three anniversaries of the grant date, subject to continuing service on the Board of Directors.
  • Resulting ownership: Following the reported transactions, Bono directly beneficially owns 78,800 shares of common stock and 157,400 derivative securities.
  • Reporting person role: Bono is identified as a Director of Vaxart, Inc. in the filing.

Raquel C. Bono's October 2026 Equity Awards at Vaxart

According to the Form 4 filed on October 20, 2026, Director Raquel C. Bono of Vaxart, Inc. (NASDAQ:VXRT) received two equity awards on October 16, 2026. The first was the acquisition of 78,800 shares of common stock at a price of $0, reported under transaction code "A," representing shares issued upon the vesting of restricted stock units. Per the filing's explanation, "the shares underlying the award shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board of Directors."

The second award was a stock option granting the right to buy 157,400 shares of common stock at an exercise price of $0.4527 per share, also at a derivative security price of $0, with an expiration date of October 16, 2036. The filing states that "the shares subject to this option shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board." Both awards are held directly by Bono.

The form was signed by Edward Berg as Attorney-in-Fact for Raquel C. Bono under a Power of Attorney listed as Exhibit 24. Following the reported transactions, Bono's directly held beneficial ownership stands at 78,800 shares of common stock and 157,400 stock options, as disclosed in the filing.

What Was Disclosed

The filing disclosed two equity grants to Vaxart Director Raquel C. Bono on October 16, 2026: 78,800 common shares from RSU vesting at $0 and a stock option for 157,400 shares at an exercise price of $0.4527, both vesting over three annual installments.